clonoSEQ
NGS-based clonotype assay for measurable/minimal residual disease assessment in lymphoid malignancies, with disease- and specimen-specific FDA-cleared contexts and additional LDT uses.
- Developer
- Adaptive Biotechnologies
- Intended use
- Mrd
- Cancer scope
- B-cell acute lymphoblastic leukemia, Chronic lymphocytic leukemia, Multiple myeloma
- Specimen
- Bone marrow aspirate, Whole blood
- Molecular modality
- DNA
- Current version
- Current clonoSEQ clinical service as of 2026-09
- Evidence context
- 1 structured studies · 0 indexed performance results · 5 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.